1. Home
  2. PB vs GKOS Comparison

PB vs GKOS Comparison

Compare PB & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prosperity Bancshares Inc.

PB

Prosperity Bancshares Inc.

HOLD

Current Price

$66.63

Market Cap

6.5B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$126.64

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PB
GKOS
Founded
1983
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.3B
IPO Year
1998
2015

Fundamental Metrics

Financial Performance
Metric
PB
GKOS
Price
$66.63
$126.64
Analyst Decision
Buy
Strong Buy
Analyst Count
13
14
Target Price
$81.17
$130.93
AVG Volume (30 Days)
784.0K
810.0K
Earning Date
01-28-2026
02-17-2026
Dividend Yield
3.18%
N/A
EPS Growth
19.26
N/A
EPS
5.60
N/A
Revenue
$1,239,671,000.00
$469,820,000.00
Revenue This Year
$8.85
$31.33
Revenue Next Year
$20.42
$24.01
P/E Ratio
$13.02
N/A
Revenue Growth
7.88
30.38
52 Week Low
$61.07
$73.16
52 Week High
$82.75
$161.78

Technical Indicators

Market Signals
Indicator
PB
GKOS
Relative Strength Index (RSI) 35.24 62.34
Support Level $71.34 $116.73
Resistance Level $73.26 $130.23
Average True Range (ATR) 1.77 6.02
MACD -0.42 0.53
Stochastic Oscillator 13.87 88.60

Price Performance

Historical Comparison
PB
GKOS

About PB Prosperity Bancshares Inc.

Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: